Janus Henderson Group PLC Increases Position in Globus Medical, Inc. $GMED

Janus Henderson Group PLC lifted its holdings in shares of Globus Medical, Inc. (NYSE:GMED) by 4.5% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 7,623,095 shares of the medical device company’s stock after buying an additional 328,217 shares during the quarter. Janus Henderson Group PLC owned approximately 0.06% of Globus Medical worth $656,831,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in GMED. Sanctuary Advisors LLC raised its stake in Globus Medical by 2.3% during the 1st quarter. Sanctuary Advisors LLC now owns 6,611 shares of the medical device company’s stock valued at $570,000 after acquiring an additional 151 shares during the last quarter. SBI Securities Co. Ltd. increased its holdings in shares of Globus Medical by 98.2% in the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 167 shares during the period. Parallel Advisors LLC raised its stake in shares of Globus Medical by 45.1% during the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after purchasing an additional 173 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Globus Medical by 74.3% during the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after purchasing an additional 197 shares during the period. Finally, Allworth Financial LP lifted its holdings in shares of Globus Medical by 1.6% during the fourth quarter. Allworth Financial LP now owns 12,545 shares of the medical device company’s stock worth $1,095,000 after purchasing an additional 199 shares during the period. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on GMED shares. BMO Capital Markets started coverage on shares of Globus Medical in a research note on Wednesday, July 8th. They issued an “outperform” rating and a $94.00 price objective on the stock. Wall Street Zen lowered shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Stifel Nicolaus cut their price target on shares of Globus Medical from $95.00 to $80.00 and set a “hold” rating for the company in a report on Wednesday, July 8th. UBS Group initiated coverage on shares of Globus Medical in a research report on Tuesday. They issued a “neutral” rating and a $82.00 price objective for the company. Finally, Truist Financial dropped their target price on Globus Medical from $115.00 to $100.00 and set a “buy” rating on the stock in a research report on Thursday, July 16th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, Globus Medical currently has an average rating of “Moderate Buy” and an average target price of $102.08.

Globus Medical Stock Performance

Shares of NYSE GMED opened at $81.32 on Thursday. Globus Medical, Inc. has a one year low of $51.79 and a one year high of $101.40. The firm has a market capitalization of $11.04 billion, a P/E ratio of 18.91, a PEG ratio of 1.66 and a beta of 0.95. The company’s fifty day moving average is $79.73 and its two-hundred day moving average is $85.76.

Globus Medical (NYSE:GMED) last announced its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The business had revenue of $759.85 million during the quarter, compared to the consensus estimate of $740.35 million. During the same quarter last year, the firm posted $0.68 EPS. The business’s revenue was up 27.0% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, sell-side analysts forecast that Globus Medical, Inc. will post 4.74 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Globus Medical news, Director David D. Davidar sold 25,000 shares of the stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $80.76, for a total value of $2,019,000.00. Following the completion of the transaction, the director directly owned 510,175 shares of the company’s stock, valued at approximately $41,201,733. This trade represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 18.38% of the company’s stock.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.